ivosidenib — United Healthcare
chondrosarcoma (bone cancer)
Initial criteria
- Diagnosis of chondrosarcoma
- Susceptible IDH1 mutation-positive
- Disease is ONE of the following: conventional (grades 1-3) OR dedifferentiated
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Tibsovo therapy
Approval duration
12 months